Browse > Article

Synthesis of $\beta$-Hydroxy-Propenamide Derivatives and the Inhibition of Human Dihydroorotate Dehydrogenase  

Kim, Taek-Hyeon (Department of Applied Chemistry, College of Engineering, Chonnam National University)
Na, Hye-Sun (Department of Applied Chemistry, College of Engineering, Chonnam National University)
Loffler, Monika (Institute for Physiological Chemistry, School of Medicine, Philipps-University)
Publication Information
Archives of Pharmacal Research / v.26, no.3, 2003 , pp. 197-201 More about this Journal
Abstract
Novel $\beta$-hydroxy propenamides as analogues of the active metabolite of leflunomide (A 771726) were synthesized and evaluated for their inhibitory activity on dihydroorotate dehydrogenase (DHODH) in an investigation into their immunosuppressive activity. Compounds 2a, 3a, and 3h were approximately 4-40 times more potent than leflunomide in their activity while they were-less active than A 771726.
Keywords
Immunosuppressive activity; A 771726; Leflunomide; Succinyl acetone; $\beta$-Hydroxy propenamides; Dihydroorotate dehydrogenase (DHODH);
Citations & Related Records

Times Cited By Web Of Science : 6  (Related Records In Web of Science)
Times Cited By SCOPUS : 2
연도 인용수 순위
1 Elison, G. B. and Hitchings G. H., Azathioprine. Handb. Exp. Pharmacol., 38, 404-425 (1975)
2 Kuo, E. A., Hambleton, P. T., Kay, D. P., Evans, P. L., Matharu, S. S., Little, E., McDowall, N., Jones, C. B., Hedgecock, C. J. R., Yea, C. M., Chan, A. W. E., Hairsine, P. W., Ager, I. R., Tully, W. R., Williamson, R. A., and Westwood, R., Synthesis, structure-activity relationship, and pharmacokinetic properties of dihydroorotate dehydrogenase inhibitors: 2-cyano-3-cyclopropyl-3-hydroxy-N-[3-methyl-4-(trifluoromethyl)phenyl] propenamide and related compounds. J. Med. Chem., 39, 4608-4621 (1996).Η⨀?ὁ⸀Ā볬蒱뷬ꂜ냪떬谀ᔀ墱䙀ᔮ쀾﷿￿￿䙇侖邝垐浇€䦍䙁?ὁ혹❁Ȁ܀ἀЀĀ?ὁ墱䙀ᔮ쀾?ὁ﷿￿￿䙇샣ʗ⨀ĀĀ侖邝垐浇ʗ⨀ᔀȀ﷿￿￿䙇äʗ⨀Ā侖邝垐浇⃤ʗ⨀ᔀ袛얖⨀䃣ʗ⨀Ȁ﷿￿￿䙇胣ʗ⨀ĀĀ侖邝垐浇ꃣʗ⨀ᔀȀ⸀볬蒱뷬ꂜ냪떬谀⸀볬蒱뷬ꂜ냪떬谀⸀볬蒱뷬ꂜ냪떬谀㄀돐샡ʗ⨀〽ʗ⨀处돀ᢰʗ⨀⁊렼ʗ⨀㄄돐éʗ⨀僠ʗ⨀   DOI   ScienceOn
3 Papageorgiou, C., Zurini, M., Weber, H.-P., and Borer, X., Leflunomides bioactive metabolite has the minimal structural requirement for the efficient inhibition of human dihydroorotate dehydrogenase. Bioorg. Chem., 25, 233-238 (1997)   DOI   ScienceOn
4 Sanders, S. and Harisdangkul, V., Leflunomide for the treatment of rheumatoid arthritis and autoimmunity. Am. J. Med. Sci., 323, 190-193 (2002)   DOI   ScienceOn
5 Skolik, S. A., Palestine, A. G., Blaese, R. M. Nussenblatt, R. B., and Hess, R. A., Treatment of experimental autoimmune uveitis in the rat with systemic succinylacetone. Clin. Immunol. Immunopathol., 49, 63-71 (1988)   DOI   ScienceOn
6 Shaw, L. M., Kaplan, B., and Kaufman, D., Toxic effects of immunosuppressive drugs: mechanism and strategies for controlling them. Clin. Chem., 42, 1316-1321 (1996)   PUBMED
7 Knecht, W., Bergjohann, U., Gonski, S., Kirschbaum, B., and L$\ddot{o}$ffler, M., Functional expression of a fragment of human dihydroorotate dehydrogenase by means of the baculovius vector system, and kinetic investigation of the purified enzyme. Eur. J. Biochem., 240, 292-301 (1996)   DOI   PUBMED   ScienceOn
8 Tschudy, D. P., Hess, R., Frykholm, B., and Blaese, R. M., Immunosuppressive activity of succinylacetone. J. Lab. Clin. Med., 99, 526-532 (1981)
9 Fidler, J. M., Chang, T. G., Bauer, R., Young, J. D., and Vitt, C. R., Suppression of graft-versus-host disease by succinylacetone in a rat allogeneic bone marrow transplantation model. Transplantation, 55, 367-373 (1993)   DOI   PUBMED   ScienceOn
10 Bertolini, G., Aquino, M., Biffi, M., dAtri, G., Di Pierro, F., Ferrario, F., Mascagni, P., Somenzi, F., Zaliani, A., and Leoni, F., A new rational hypothesis for the pharmacophore of the active metabolite of leflunomide, a potent immunosuppressive drug. J. Med. Chem., 40, 2011-2016 (1997)   DOI   ScienceOn
11 Hess, R. A., Tschudy, D. P., and Blaese, R. M., Immunosuppression by succinylacetone: II. prevention of graft-vs-host disease. J. Immunol., 139, 2845-2849 (1987)   PUBMED
12 Jones, M. E., Pyrimidine nucleotide biosynthesis in animals, genes, enzymes, and regulation of UMP biosynthesis. Annu, Rev. Biochem., 49, 253-256 (1980)   DOI   PUBMED   ScienceOn
13 Davis, J. F., Cain, G. A., Pitts, W. J., Magolda, R. L., and Copeland, R. A., The immunosuppressive metabolite of leflunomide is a potent inhibitor of human dihydroorotate dehydrogenase. Biochemistry, 35, 1270-1273 (1996)   DOI   ScienceOn
14 Knecht, W. and L$\ddot{o}$ffler, M., Species-related inhibition of human and rat dihydroorotate dehydrogenase by immunosuppressive isoxazole and cinchoninic acid derivatives. Biochem. Pharmacol., 56, 1259-1264 (1998)   DOI   PUBMED   ScienceOn
15 Tanaka, H., Kuroda, A., Marusawa, H., Hatanaka, H., Kino, T., Goto, T., Hashimoto, M., and Taga, T., Structure of FK506: a novel immunosuppressants isolated from Streptomyces. J. Am. Chem. Soc., 109, 5031-5033 (1987)   DOI
16 Perico, N. and Remuzzi, G., Prevention of transplant rejection current treatment guidelines and future developments. Drugs, 54, 533-570 (1997)   DOI   ScienceOn
17 Lindblad, B., Lindstedt, S., and Steen, G., On the enzyme defects in hereditary tyrosinemia. Proc. Natl. Acad. Sci. USA, 74, 4641-4645 (1977)   DOI   ScienceOn
18 Borel, J. F., History of cyclosporin A and its significance in immunology. In cyclosporin A, Borel, J. F., Ed.; Elsevier Biochemical Press: Amsterdam, 1982, pp 5-17